�Ӱ���Ƶ

One of the earliest known impairments caused by Alzheimer’s disease—loss of sense of smell—can be restored by removing a plaque-forming protein in a mouse model of the disease, a study led by a �Ӱ���Ƶ School of Medicine researcher finds. The study confirms that the protein,...

�Ӱ���Ƶ School of Medicine has received a $3.8 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study sleep apnea as a possible cause of atrial fibrillation (AF), the most commonly diagnosed type of arrhythmia, or irregular heart rhythm. AF is char...

CLEVELAND - �Ӱ���Ƶ School of Medicine has received a $3.8 million grant from the National Heart, Lung, and Blood Institute (NHLBI) to study sleep apnea as a possible cause of atrial fibrillation (AF), the most commonly diagnosed type of arrhythmia, or irregular heart rhythm....

CLEVELAND - University Hospitals (UH) Case Medical Center, �Ӱ���Ƶ School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting t...

A new study of teens undergoing substance abuse treatment finds helping others helps the adolescent helper by reducing cravings for alcohol and drugs, a major precipitator of relapse. These novel findings stem from the “Helping Others” study (helpingotherslivesober.org) led by Maria Pagano, PhD, ass...

CLEVELAND - Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio, which is co-sponsored by �Ӱ���Ƶ School of Medicine. More than 80 abstracts will be presented at the annual ...

CLEVELAND - �Ӱ���Ƶ School of Medicine is honored to announce gifts to establish the inaugural Parker Hannifin – Helen Moss Cancer Research Foundation Professorship in Integrative Oncology. This professorship will establish the School of Medicine and its affiliate hospitals a...

CLEVELAND - Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medication ivacaftor (VX-770) provides major, sustained improvement in lung function, growth and other signs and symptoms for cystic fibrosis (CF) patients. The...

Research from �Ӱ���Ƶ School of Dental Medicine to study an isolated agent from common oral bacteria may hold the answer as to how human beta defensins (HBDs)—nature’s way of keeping oral microbes from entering the body and wreaking havoc on our health—can be used to create n...

Osteoporosis is blamed for backbone fractures. The real culprit could well be our own vertebrae, which evolved to absorb the pounding of upright walking, researchers at �Ӱ���Ƶ say. Compared to apes, humans have larger, more porous vertebrae encased in a much thinner shell o...